Critical therapeutic categories: a contraindication to generic substitution?

Area of Science:

• Pharmacology and Pharmaceutics
• Drug Safety and Regulation

Background:

• Generic drug substitution is permitted or required in all 50 states, with physician override.
• Substitution poses risks of treatment failure and toxicity for specific drug classes and patient groups.

Purpose of the Study:

• To highlight the potential risks associated with generic drug substitution.
• To advise caution in prescribing and dispensing substituted generic drugs.

Main Methods:

• Review of current state regulations on generic drug substitution.
• Analysis of the FDA's bioequivalence standards for generic drug approval.
• Identification of critical therapeutic categories and at-risk patient populations.

Main Results:

• Substitution risks are elevated for cardiovascular, psychotropic, and anticonvulsant medications.
• Elderly or debilitated patients with impaired organ function are particularly vulnerable.
• FDA's bioequivalence criteria may allow significant absorption variability (40-60%) between generic drug versions.

Conclusions:

• Indiscriminate switching between generic products can lead to significant therapeutic variability.
• Caution is urged for substituted drugs requiring precise titration, especially in critical categories and for at-risk patients.
• The FDA is currently re-evaluating its generic drug approval policies.